Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| A2581145 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To investigate whether a long-term strategy to lower LDL cholesterol with atorvastatin as much as possible will improve prognosis in CHD patients compared with a strategy reflecting current best clinical practice with simvastatin.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| atorvastatin | Drug | |||
| simvastatin | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Time to of a major coronary event: 1) non-fatal acute myocardial infarction 2) coronary death 3) resuscitated cardiac arrest |
| Measure | Description | Time Frame |
|---|---|---|
| 1) Time to any CHD event, 2) Time to Hospitalization with primary diagnosis of CHF, 3) Time to Cerbrovascular Event, 4) Time to PAD, 5) Time to any CV event and 6) All Cause Mortality |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Arhus C | DK-8000 | Denmark | |||
| Pfizer Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 16287954 | Result | Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2437-45. doi: 10.1001/jama.294.19.2437. | |
| 38018702 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Copenhagen |
| 2100 |
| Denmark |
| Pfizer Investigational Site | Elsinore | 3000 | Denmark |
| Pfizer Investigational Site | Esbjerg | 6700 | Denmark |
| Pfizer Investigational Site | Fredericia | 7000 | Denmark |
| Pfizer Investigational Site | Frederiksberg | 2000 | Denmark |
| Pfizer Investigational Site | Frederikssund | 3600 | Denmark |
| Pfizer Investigational Site | Grenå | 8500 | Denmark |
| Pfizer Investigational Site | Hjørring | 9800 | Denmark |
| Pfizer Investigational Site | Holbak | 4300 | Denmark |
| Pfizer Investigational Site | Holstebro | 7500 | Denmark |
| Pfizer Investigational Site | Hvidovre | 2650 | Denmark |
| Pfizer Investigational Site | Kabenhavn S | 2300 | Denmark |
| Pfizer Investigational Site | Kalundborg | 4400 | Denmark |
| Pfizer Investigational Site | København NV | 2400 | Denmark |
| Pfizer Investigational Site | Kobenhavn K | 1256 | Denmark |
| Pfizer Investigational Site | København NV | 2400 | Denmark |
| Pfizer Investigational Site | Køge | 4600 | Denmark |
| Pfizer Investigational Site | Middelfart | 5500 | Denmark |
| Pfizer Investigational Site | Nykøbing Falster | 4800 | Denmark |
| Pfizer Investigational Site | Næstved | 4700 | Denmark |
| Pfizer Investigational Site | Odder | 8300 | Denmark |
| Pfizer Investigational Site | Randers | 8900 | Denmark |
| Pfizer Investigational Site | Roskilde | 4000 | Denmark |
| Pfizer Investigational Site | Silkeborg | 8600 | Denmark |
| Pfizer Investigational Site | Skive | 7800 | Denmark |
| Pfizer Investigational Site | Slagelse | 4200 | Denmark |
| Pfizer Investigational Site | Svendborg | 5700 | Denmark |
| Pfizer Investigational Site | Ekenäs | 10600 | Finland |
| Pfizer Investigational Site | Heinola | 18100 | Finland |
| Pfizer Investigational Site | Helsinki | 00029 | Finland |
| Pfizer Investigational Site | Helsinki | 00100 | Finland |
| Pfizer Investigational Site | Joensuu | 80210 | Finland |
| Pfizer Investigational Site | Jyväskylä | 40100 | Finland |
| Pfizer Investigational Site | Kerava | 04200 | Finland |
| Pfizer Investigational Site | Kuopio | 70210 | Finland |
| Pfizer Investigational Site | Lahti | 15110 | Finland |
| Pfizer Investigational Site | Lappeenranta | 53130 | Finland |
| Pfizer Investigational Site | Lohja | 08200 | Finland |
| Pfizer Investigational Site | Mikkeli | 50100 | Finland |
| Pfizer Investigational Site | Rauma | 26100 | Finland |
| Pfizer Investigational Site | Salo | 24130 | Finland |
| Pfizer Investigational Site | Siaraalamaki | 45750 | Finland |
| Pfizer Investigational Site | Tampere | 33520 | Finland |
| Pfizer Investigational Site | Vantaa | 01400 | Finland |
| Pfizer Investigational Site | Reykjavik | 101 | Iceland |
| Pfizer Investigational Site | Reykjavik | 108 | Iceland |
| Pfizer Investigational Site | 's-Hertogenbosch | 5211 NL | Netherlands |
| Pfizer Investigational Site | Alkmaar | 1815 JD | Netherlands |
| Pfizer Investigational Site | Amsterdam | 1061 AE | Netherlands |
| Pfizer Investigational Site | Assen | 9401 RK | Netherlands |
| Pfizer Investigational Site | Breda | 4818 CK | Netherlands |
| Pfizer Investigational Site | Capelle aan den IJssel | 2906 ZC | Netherlands |
| Pfizer Investigational Site | Delft | 2625 AD | Netherlands |
| Pfizer Investigational Site | Deventer | 7415 CM | Netherlands |
| Pfizer Investigational Site | Ede | 6716 RP | Netherlands |
| Pfizer Investigational Site | Eindhoven | 5623 EJ | Netherlands |
| Pfizer Investigational Site | Enschede | 7511 JX | Netherlands |
| Pfizer Investigational Site | Goes | 4462 RA | Netherlands |
| Pfizer Investigational Site | Groningen | 9721 SW | Netherlands |
| Pfizer Investigational Site | Hoorn | 1624 GM | Netherlands |
| Pfizer Investigational Site | Nijmegen | 6532 SZ | Netherlands |
| Pfizer Investigational Site | Oss | NL-5342 BT | Netherlands |
| Pfizer Investigational Site | Rotterdam | 3045 PM | Netherlands |
| Pfizer Investigational Site | Tilburg | 5022 GC | Netherlands |
| Pfizer Investigational Site | Tilurg | 5022 GC | Netherlands |
| Pfizer Investigational Site | Utrecht | NL-3508-TG | Netherlands |
| Pfizer Investigational Site | Weert | 6001 BE | Netherlands |
| Pfizer Investigational Site | Zwijndrecht | 3331 LZ | Netherlands |
| Pfizer Investigational Site | Zwolle | 8011 JW | Netherlands |
| Pfizer Investigational Site | Ålesund | 6002 | Norway |
| Pfizer Investigational Site | Ålesund | 6026 | Norway |
| Pfizer Investigational Site | Bergen | 5008 | Norway |
| Pfizer Investigational Site | Bergen | 5009 | Norway |
| Pfizer Investigational Site | Bergen | 5012 | Norway |
| Pfizer Investigational Site | Bergen | 5015 | Norway |
| Pfizer Investigational Site | Bergen | 5021 | Norway |
| Pfizer Investigational Site | Bodø | 8092 | Norway |
| Pfizer Investigational Site | Flekkefjord | 4400 | Norway |
| Pfizer Investigational Site | Førde | 6807 | Norway |
| Pfizer Investigational Site | Hammerfest | 9613 | Norway |
| Pfizer Investigational Site | Haugesund | 5500 | Norway |
| Pfizer Investigational Site | Hobøl | 1827 | Norway |
| Pfizer Investigational Site | Jessheim | 2050 | Norway |
| Pfizer Investigational Site | Karasjok | 9735 | Norway |
| Pfizer Investigational Site | Kongsberg | 3600 | Norway |
| Pfizer Investigational Site | Kongsvinger | 2226 | Norway |
| Pfizer Investigational Site | Kragerø | 3770 | Norway |
| Pfizer Investigational Site | Kristiansand | 4612 | Norway |
| Pfizer Investigational Site | Kristiansund N | 6508 | Norway |
| Pfizer Investigational Site | Larvik | 3257 | Norway |
| Pfizer Investigational Site | Levanger | 7600 | Norway |
| Pfizer Investigational Site | Lillestom | 2000 | Norway |
| Pfizer Investigational Site | Lorenskog | 1478 | Norway |
| Pfizer Investigational Site | Mo i Rana | 8607 | Norway |
| Pfizer Investigational Site | Molde | 6407 | Norway |
| Pfizer Investigational Site | Molde | 6415 | Norway |
| Pfizer Investigational Site | Mosjøen | 8656 | Norway |
| Pfizer Investigational Site | Moss | 1502 | Norway |
| Pfizer Investigational Site | Mysen | 1850 | Norway |
| Pfizer Investigational Site | Nesttun | 5221 | Norway |
| Pfizer Investigational Site | Notodden | 3675 | Norway |
| Pfizer Investigational Site | Odda | 5750 | Norway |
| Pfizer Investigational Site | Oslo | 0027 | Norway |
| Pfizer Investigational Site | Oslo | 0160 | Norway |
| Pfizer Investigational Site | Oslo | 0264 | Norway |
| Pfizer Investigational Site | Oslo | 0303 | Norway |
| Pfizer Investigational Site | Oslo | 0407 | Norway |
| Pfizer Investigational Site | Oslo | 0456 | Norway |
| Pfizer Investigational Site | Oslo | 0514 | Norway |
| Pfizer Investigational Site | Oslo | 0913 | Norway |
| Pfizer Investigational Site | Paradis | 5231 | Norway |
| Pfizer Investigational Site | Porsgrunn | 3922 | Norway |
| Pfizer Investigational Site | Rud | 1309 | Norway |
| Pfizer Investigational Site | Sandvika | 1301 | Norway |
| Pfizer Investigational Site | Skedsmokorset | N-2020 | Norway |
| Pfizer Investigational Site | Ski | 1400 | Norway |
| Pfizer Investigational Site | Stavanger | 4004 | Norway |
| Pfizer Investigational Site | Stavanger | 4006 | Norway |
| Pfizer Investigational Site | Stavanger | 4023 | Norway |
| Pfizer Investigational Site | Stavanger | 4095 | Norway |
| Pfizer Investigational Site | Stord | 5400 | Norway |
| Pfizer Investigational Site | Tansberg | 3191 | Norway |
| Pfizer Investigational Site | Trondheim | 7001 | Norway |
| Pfizer Investigational Site | Trondheim | 7011 | Norway |
| Pfizer Investigational Site | Tynset | 2500 | Norway |
| Pfizer Investigational Site | Tønsberg | 3103 | Norway |
| Pfizer Investigational Site | Volda | 6100 | Norway |
| Pfizer Investigational Site | Alingsås | 441 83 | Sweden |
| Pfizer Investigational Site | Ängelholm | 262 81 | Sweden |
| Pfizer Investigational Site | Bålsta | 746 32 | Sweden |
| Pfizer Investigational Site | Borås | 501 82 | Sweden |
| Pfizer Investigational Site | Eksjö | 575 81 | Sweden |
| Pfizer Investigational Site | Eskilstuna | 631 88 | Sweden |
| Pfizer Investigational Site | Fagersta | 737 81 | Sweden |
| Pfizer Investigational Site | Falköping | 521 85 | Sweden |
| Pfizer Investigational Site | Falun | 791 82 | Sweden |
| Pfizer Investigational Site | Finspång | 612 25 | Sweden |
| Pfizer Investigational Site | Gateborg | 41345 | Sweden |
| Pfizer Investigational Site | Gävle | 800 02 | Sweden |
| Pfizer Investigational Site | Gävle | 801 87 | Sweden |
| Pfizer Investigational Site | Gävle | 802 57 | Sweden |
| Pfizer Investigational Site | Gävle | 802 84 | Sweden |
| Pfizer Investigational Site | Gothenburg | 413 45 | Sweden |
| Pfizer Investigational Site | Gothenburg | 417 17 | Sweden |
| Pfizer Investigational Site | Grästorp | 46722 | Sweden |
| Pfizer Investigational Site | Halmstad | 301 85 | Sweden |
| Pfizer Investigational Site | Hässleholm | 281 25 | Sweden |
| Pfizer Investigational Site | Hässleholm | 281 31 | Sweden |
| Pfizer Investigational Site | Helsingborg | 252 20 | Sweden |
| Pfizer Investigational Site | Helsingborg | 252 21 | Sweden |
| Pfizer Investigational Site | Hudiksvall | 824 81 | Sweden |
| Pfizer Investigational Site | Jönköping | 55185 | Sweden |
| Pfizer Investigational Site | Kalmar | 391 85 | Sweden |
| Pfizer Investigational Site | Karlshamn | 374 80 | Sweden |
| Pfizer Investigational Site | Karlskoga | S-691 81 | Sweden |
| Pfizer Investigational Site | Karlskrona | 371 85 | Sweden |
| Pfizer Investigational Site | Karlstad | 651 85 | Sweden |
| Pfizer Investigational Site | Katarineholm | 641 22 | Sweden |
| Pfizer Investigational Site | Köping | 731 80 | Sweden |
| Pfizer Investigational Site | Kristinehamn | 681 80 | Sweden |
| Pfizer Investigational Site | Lidköping | 531 85 | Sweden |
| Pfizer Investigational Site | Linka Ping | 581 85 | Sweden |
| Pfizer Investigational Site | Ljungby | 341 82 | Sweden |
| Pfizer Investigational Site | Ludvika | 771 81 | Sweden |
| Pfizer Investigational Site | Luleå | 971 80 | Sweden |
| Pfizer Investigational Site | Lycksele | 921 82 | Sweden |
| Pfizer Investigational Site | Malmö | 205 02 | Sweden |
| Pfizer Investigational Site | Malmö | 211 20 | Sweden |
| Pfizer Investigational Site | Malmö | 211 38 | Sweden |
| Pfizer Investigational Site | Malmö | 214 22 | Sweden |
| Pfizer Investigational Site | Mariestad | 542 24 | Sweden |
| Pfizer Investigational Site | Motala | 591 85 | Sweden |
| Pfizer Investigational Site | Mölndal | 431 80 | Sweden |
| Pfizer Investigational Site | Norrköping | 601 82 | Sweden |
| Pfizer Investigational Site | Sala | 733 25 | Sweden |
| Pfizer Investigational Site | Sandviken | 811 89 | Sweden |
| Pfizer Investigational Site | Skellefteå | 931 86 | Sweden |
| Pfizer Investigational Site | Skene | 511 81 | Sweden |
| Pfizer Investigational Site | Skövde | 541 85 | Sweden |
| Pfizer Investigational Site | Södertälje | 151 72 | Sweden |
| Pfizer Investigational Site | Stockholm | 111 35 | Sweden |
| Pfizer Investigational Site | Stockholm | 113 22 | Sweden |
| Pfizer Investigational Site | Stockholm | 113 82 | Sweden |
| Pfizer Investigational Site | Stockholm | 114 86 | Sweden |
| Pfizer Investigational Site | Stockholm | 116 25 | Sweden |
| Pfizer Investigational Site | Stockholm | 118 83 | Sweden |
| Pfizer Investigational Site | Strömstad | 452 83 | Sweden |
| Pfizer Investigational Site | Uddevalla | 451 80 | Sweden |
| Pfizer Investigational Site | Umeå | 901 85 | Sweden |
| Pfizer Investigational Site | Varberg | 432 81 | Sweden |
| Pfizer Investigational Site | Vänersborg | 46235 | Sweden |
| Pfizer Investigational Site | Västervik | 593 81 | Sweden |
| Pfizer Investigational Site |
| Derived |
| Tunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3. |
| 28573499 | Derived | Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0. |
| 28214794 | Derived | Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb 18;6(2):e004648. doi: 10.1161/JAHA.116.004648. |
| 27513651 | Derived | Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30. |
| 25595417 | Derived | Stoekenbroek RM, Boekholdt SM, Fayyad R, Laskey R, Tikkanen MJ, Pedersen TR, Hovingh GK; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart. 2015 Mar;101(5):356-62. doi: 10.1136/heartjnl-2014-306906. Epub 2015 Jan 16. |
| 23674398 | Derived | Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14. |
| 22576673 | Derived | Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep;64(9):2836-46. doi: 10.1002/art.34524. |
| 20130232 | Derived | Hyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010 Apr;3(2):162-8. doi: 10.1161/CIRCGENETICS.109.897793. Epub 2010 Feb 3. |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| D019821 | Simvastatin |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006538 | Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D008148 | Lovastatin |
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011083 | Polycyclic Compounds |
Not provided
Not provided